1443.3: A Phase 1 PET imaging study to investigate the biodistribution and tumor uptake of [89Zr]-BI 765063^a and [89Zr]-BI 770371^a in patients with HNSCC, NSCLC, or melanoma who are treated with ezabenlimab (PD-1 inhibitor)^1,2

Zoom

1. NCT05068102. https://clinicaltrials.gov/ct2/show/study/NCT05068102. Accessed September 2023; 2. Boehringer Ingelheim. Data on file.